Cantor Fitzgerald Assumes Aimmune Therapeutics (AIMT) at Overweight
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 8
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 10 | New: 8
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan assumes coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $64.00.
For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.
Shares of Aimmune Therapeutics closed at $23.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Alliance Global Partners Starts Momentus (MNTS) at Buy
- Cantor Fitzgerald Downgrades Better Home & Finance Holding (BETR) to Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Cantor Fitzgerald, Charles DuncanSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
